After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI projects, and have therefore decided to close them down,” commented Anders Lundström, President and CEO of Orexo. The original deal, signed in June 2010, could have been worth around €450m to the Swedish drugmaker. A third, undisclosed Janssen programme was also terminated. OX-CLI (LCT4 inhibitor) and OX-ESI (15-LO inhibitor) focussed on the development of drugs acting in the arachidonic acid cascade to treat asthma, chronic obstructive pulmonary disease and other inflammatory diseases. Orexo and Janssen have regained full commercial rights for their respective drug discovery programmes.